Comparative Pharmacology
Head-to-head clinical analysis: KISQALI versus PALBOCICLIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KISQALI versus PALBOCICLIB.
KISQALI vs PALBOCICLIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Kisqali (ribociclib) selectively inhibits CDK4 and CDK6, which are involved in cell cycle progression. By inhibiting these kinases, it reduces retinoblastoma protein (Rb) phosphorylation, leading to cell cycle arrest in the G1 phase and reduced proliferation of cancer cells.
Cyclin-dependent kinase (CDK) 4 and 6 inhibitor; blocks phosphorylation of retinoblastoma protein, preventing cell cycle progression from G1 to S phase.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle), in combination with an aromatase inhibitor or fulvestrant.
125 mg orally once daily for 21 days, followed by 7 days off treatment; taken with food in combination with an aromatase inhibitor or fulvestrant.
None Documented
None Documented
Clinical Note
moderatePalbociclib + Deslanoside
"Palbociclib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePalbociclib + Acetyldigitoxin
"Palbociclib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderatePalbociclib + Ouabain
"Palbociclib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderatePalbociclib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Palbociclib."
Terminal half-life is approximately 32 hours (range 29-40 hours) after oral administration, supporting once-daily dosing. The long half-life allows for steady-state achievement within 8 days.
Terminal elimination half-life of 24-29 hours, supporting once-daily dosing; steady-state reached within 8 days.
Primarily hepatic metabolism via CYP3A4, with 69% of dose eliminated in feces (as unchanged drug and metabolites) and 23% in urine (mostly as metabolites). Unchanged ribociclib accounts for <10% of excreted drug.
Primarily hepatic metabolism (CYP3A4) with 74% fecal excretion (17% as unchanged drug) and 18% renal excretion (1.5% unchanged).
Category C
Category D/X
CDK4/6 Inhibitor Antineoplastic
CDK4/6 Inhibitor